MedTrace Logo

Newborn Screening Assay of Pompe's Disease

NCT01758354 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 236536

Last updated 2013-01-01

No results posted yet for this study

Summary

The purpose of this study is to test the feasibility of a newborn screen assay for Pompe disease

Conditions

  • Pompe Disease

Interventions

OTHER

Pompe disease newborn screening

DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Whu-Liang Hwu, MD, PhD · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01758354 on ClinicalTrials.gov